SCHEMBL446291

SCHEMBL446291

NC(=O)c1ccc2[nH]nnc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
CHEK2 O96017 8/20 0.41
MAP2K4 P45985 3/20 0.40
MAPK1 P28482 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
MAPKAPK3 Q16644 1/20 0.40
MAPK6 Q16659 1/20 0.40
MAPKAPK5 Q8IW41 1/20 0.40
PKN1 Q16512 1/20 0.40
PKN2 Q16513 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
HTR1A P08908 1/20 0.39
TSHR P16473 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9172322 0.98 MMP2 (0.41) MMP2MMP13CHEK2MAP2K4MAPK1
SCHEMBL29751019 0.86 CHEK2 (0.48) CHEK2PKN1PKN2CHEK1
SCHEMBL446292 0.86 CHEK2 (0.48) CHEK2PKN1PKN2CHEK1
SCHEMBL119640 0.84 TDP1 (0.44) KMT2AMEN1TSHRHSD17B10
Ammonia Solution, Strong SCHEMBL6052079 0.82 TDP1 (0.43) KMT2AMEN1HSD17B10CD40CD40LG
SCHEMBL8424370 0.82 TDP1 (0.43) KMT2AMEN1HSD17B10CD40CD40LG
Water SCHEMBL30938808 0.82 TDP1 (0.43) KMT2AMEN1HSD17B10CD40CD40LG
SCHEMBL3726621 0.82 SLC2A1 (0.41) HTR1AHTR1DHTR1BCD40CD40LG
SCHEMBL6216873 0.82 F2 (0.46)
SCHEMBL7325912 0.82 CD40 (0.38) TSHRCD40CD40LG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 EP claimed
EP-3275440-B1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NAT CT GERIATRICS & GERONTOLOGY (JP) 2022-05-04 EP claimed
EP-3849552-A1 COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF Rhizen Pharmaceuticals AG (CH) 2021-07-21 EP claimed
WO-2020053834-A1 COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF RHIZEN PHARMACEUTICALS SA (CH) 2020-03-19 WO claimed
WO-2015187827-A1 NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-12-10 WO claimed
CN-101686979-A The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces JANSSEN PHARMACEUTICA NV 2010-03-31 CN claimed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US claimed
EP-1893599-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2007092403-A1 N-PHENYLBENZOTRIAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-08-16 WO claimed
WO-2006134378-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
JP-10077412-A None JP disclosed
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-111801322-B Kinase inhibitors for the treatment of central and peripheral nervous system disorders 迈阿密大学 2024-03-15 CN disclosed
WO-2024043741-A1 AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 주식회사 레고켐 바이오사이언스 2024-02-29 WO disclosed
US-11851428-B2 Activator of TREK (TWIK RElated K+channels) channels ONO PHARMACEUTICAL CO., LTD. (JP) 2023-12-26 US disclosed
EP-0822234-A1 Addition-curable silicone elastomers having a reduced compression set Wacker-Chemie GmbH (DE) 1998-02-04 EP disclosed
EP-0131161-B1 HEAT-DEVELOPABLE COLOR PHOTOSENSITIVE ELEMENT KONICA CORPORATION (JP) 1988-11-02 EP disclosed
US-4770989-A USING A THERMAL SOLVENT AND GELATIN/POLYVINYPYRROLIDONE POLYMER MIXTURE; DIFFUSION TRANSFER QUALITY IMAGE KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1988-09-13 US disclosed
US-4649096-A EXPOSURE, DEVELOPMENT, ALKALI HYDROXIDE, ALKANOLAMINE, SULFITE, THIOSULFATE, P-DIHYDROXYBENZENE MITSUBISHI PAPER MILLS, LTD. (JP) 1987-03-10 US disclosed
EP-0131161-A2 Heat-developable color photosensitive element KONICA CORPORATION (JP) 1985-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851428-B2 Activator of TREK (TWIK RElated K+channels) channels KCNJ11, KCNJ1, KCNJ8 MMP2 3731/4885MMP13 4021/4885CHEK2 1202/4885
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 MMP2 3368/4885MMP13 3082/4885CHEK2 1483/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 MMP2 3926/4885MMP13 3846/4885CHEK2 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.